cbdMD Inc. reported a 12% sequential increase in revenue for the first quarter ended December 31, 2025, reflecting continued stabilization of its core business. In December 2025, the company raised approximately USD 2.25 million in Series C preferred financing to improve liquidity and working capital. cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026, adding e-commerce operations and valuable intellectual property, including GRAS status for full-spectrum CBD formulations. Integration efforts are underway with a focus on operational efficiencies, cost synergies, and revenue optimization. The company also noted its strongest December and January performance in the past three years and expressed confidence in its positioning for improved operating results and sustainable profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171610PR_NEWS_USPR_____CL89656) on February 17, 2026, and is solely responsible for the information contained therein.